Good catch, Jimbo. This quote on the PR from Biogen regarding the conditional nature of the approval in Canada: "LEQEMBI has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Eisai plans to submit clinical assessment data captured from participants in real-world clinical practice."
Market Data 
Markets 
AI
